Avelumab
Therapeutic Avelumab antibody from the original Bavencio® commercial drug.
Reference Standard as Aliquots
Product Batch | Therapeutic Expiry Date
| Brand & Origin
| Amount per Aliquot
| Select Quantity | Discount | Price per Aliquot
| |
|---|---|---|---|---|---|---|---|
2021.01 |
Bavencio® DE |
2 mg |
Unit: aliquot(s) |
143,00 €
/aliquot
|
Biosimilars as Aliquots
Access Batch Specific Analytical Information
Evidentic’s Analytical Data Service includes a comprehensive array of methods to support the drug development process, including structure, aggregation, degree of isomerization, and N-glycans identification of the active pharmaceutical ingredient (API).
Product Information
Here you will find the product information for the reference product.
Bavencio® / Avelumab Reference Product
| Drug name | Bavencio® |
| INN | Avelumab |
| API type | Avelumab is a human monoclonal IgG1 antibody directed against the immunomodulatory cell surface ligand protein PD-L1 and produced in Chinese hamster ovary cells by recombinant DNA technology. |
| Pharmacotherapeutic group | Antineoplastic agents, monoclonal antibodies |
| ATC code | L01XC31 |
| Target of antibody | PD-L1; Synonyms: CD274, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1, PDL1, A530045L16Rik, B7h1, Pdcd1l1, Pdcd1lg1, Pdl1, RGD1566211 |
| General function | Avelumab is used to treat adults with Merkel cell carcinoma (MCC), a rare type of skin cancer when it is metastatic (has spread to other parts of the body). PD-L1 is found on the surface of MCC cells and helps protect tumour cells from the immune system (the body’s natural defences). Avelumab binds to PD-L1, and blocks this protective effect, allowing the immune system to attack the tumour cells. (Source EMA , package leaflet) |
| Short description | |
| Pharmacodynamic properties (Mechanism of action; Source EMA document) | Avelumab is a human immunoglobulin G1 (IgG1) monoclonal antibody directed against programmed death ligand 1 (PD-L1). Avelumab binds PD-L1 and blocks the interaction between PD-L1 and the programmed death 1 (PD-1) and B7.1 receptors. This removes the suppressive effects of PD-L1 on cytotoxic CD8+ T-cells, resulting in the restoration of anti-tumour T-cell responses. |
| Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document) | Avelumab has also shown to induce natural killer (NK) cell-mediated direct tumour cell lysis via antibody-dependent cell-mediated cytotoxicity (ADCC). |
| Original license holder | Merck Europe B.V. |
| Marketing authorisation numbers | EU/1/17/1214/001 |
| Marketing authorisation holder | Merck Europe B.V. Gustav Mahlerplein 102 1082 MA Amsterdam The Netherlands |
| Name of the manufacturer of the biological active substance | Merck Serono SA Succursale de Corsier-sur-Vevey Chemin du Fenil - Zone Industrielle B, 1804 Corsier-sur-Vevey Switzerland |
| Name and address of the manufacturer(s) responsible for batch release | Merck Serono S.p.A. Via Delle Magnolie 15 (loc. frazione Zona Industriale) 70026 - Modugno (BA) Italy |
| Max shelf life | 24 months |
| Storage conditions | 2°C – 8°C |
| List of excipients | Mannitol Glacial acetic acid Polysorbate 20 Sodium hydroxide |
Support
Do you have a question about the product? Reach out to our team using the form below – we’d be happy to help you!
Ready to simplify your sourcing?
Here’s how to get started:
Select Your Licensed Molecules
Browse our shop and choose the licensed molecule(s) you need. Don’t worry if you can’t find the molecule you’re looking for – we can source it for you!
Get a Quote
Receive a confidential, non-binding quote for the molecule(s) you choose.
Get Qualified & We Deliver
Complete our quick qualification process, place your order, and we’ll ship your molecule(s) within days.
Do you have a question you'd like to ask us?
Here’s how to get started:
